EGFR and non-small cell lung carcinoma: Tailored therapies, especially for non-squamous NSCLC with EGFR mutations, and the use of monoclonal antibodies like bevacizumab and ALK inhibitors have shown promising results in specific subtypes [9,10,11,12].